Nicotinic Acetylcholine Receptor Mechanisms in Alzheimer’s Disease

Alzheimer’s disease (AD) is characterised by progressive cognitive decline, synaptic loss and neuroinflammation. Central to these processes is the cholinergic system, in which nicotinic acetylcholine receptors (nAChRs) regulate neurotransmission, calcium signalling and immune responses. Among the diverse nAChR subtypes, the homomeric α7 receptor has attracted particular interest because of its high calcium permeability and anti-inflammatory signalling through the cholinergic anti-inflammatory pathway. Early in AD, levels of α7 nAChRs and other high-affinity subtypes decline in both synaptic and mitochondrial membranes, coinciding with deposition of amyloid-β (Aβ) and hyperphosphorylation of tau. Aβ peptides interact directly with nAChRs, behaving as both agonists at picomolar concentrations and negative modulators at higher levels, thus contributing to receptor desensitisation and synaptic dysfunction. Genetic studies link CHRNA5 variants to altered α5-subunit expression in chandelier interneurons, which in turn correlates with cortical Aβ load and neuronal vulnerability. Membrane lipid microdomains further modulate Aβ processing and nAChR localisation, affecting receptor function and Aβ accumulation. Preclinical interventions using α7-selective agonists and co-activation strategies targeting both α7 and α4β2 receptors have demonstrated rescue of synaptic plasticity, reduction of neuroinflammation and improvement of cognition. These insights underscore nAChRs as early biomarkers and therapeutic targets for mitigating synaptic failure and neurodegeneration in AD.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Nicotinic Acetylcholine Receptor Mechanisms in Alzheimer’s Disease publication trend

The graph below shows the total number of articles in nicotinic acetylcholine receptor mechanisms in alzheimer’s disease across all publications each year (not limited to Nature Index journals).

Technical terms

nicotinic acetylcholine receptor (nAChR): A ligand-gated ion channel activated by acetylcholine or nicotine, involved in fast synaptic transmission and neuromodulation.

α7 nAChR: A homomeric subtype of nAChR with high calcium permeability, implicated in synaptic plasticity, anti-inflammatory signalling and cognitive processes.

amyloid-β (Aβ): Peptides derived from amyloid precursor protein that aggregate extracellularly in AD, exerting neurotoxic and receptor-modulating effects.

lipid rafts: Cholesterol- and sphingolipid-rich microdomains of the plasma membrane that organise receptor localisation and influence signal transduction.

chandelier neuron: A specialised inhibitory interneuron in the cerebral cortex characterised by vertically oriented axonal cartridges that regulate pyramidal cell output.

References

1. Impairment of brain function in a mouse model of Alzheimer's disease during the pre-depositing phase: The role of α7 nicotinic acetylcholine receptors. Biomedicine & Pharmacotherapy (2024).
2. CHRNA5 links chandelier cells to severity of amyloid pathology in aging and Alzheimer’s disease. Translational Psychiatry (2024).
3. Alzheimer’s Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. Frontiers in Cellular Neuroscience (2019).
4. Molecular Modulation of Human α7 Nicotinic Receptor by Amyloid-β Peptides. Frontiers in Cellular Neuroscience (2019).
5. Selective coactivation of α7- and α4β2-nicotinic acetylcholine receptors reverses beta-amyloid–induced synaptic dysfunction. Journal of Biological Chemistry (2021).